By Melane Sampson
Senti Biosciences (NASDAQ: SNTI) is developing a new generation of cell and gene therapies designed to bring greater precision, control, and safety to the treatment of difficult-to-treat cancers and other incurable diseases. By leveraging its synthetic biology platform, the company is engineering gene circuits into therapeutic cells, enabling them to sense their environment, compute biological signals, and respond selectively inside the body.
“Our approach represents an effort to move beyond conventional cell therapy design by programming living cells with increasingly sophisticated biological instructions,” Timothy Lu, MD, PhD, co-founder and CEO of Senti Biosciences, says in an interview with BioTuesdays.
“Our gene circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target tissues, and remain controllable even after administration,” he adds.
Dr. Lu describes the company’s approach as programming living cells much like computers. “The idea is to engineer cells that can go into the body, sense the environment they encounter, make decisions, and then execute specific functions based on that information.”
He explains that the scientific foundation for the company originated from early work in synthetic biology, where researchers first demonstrated the ability to program simple organisms such as E coli. Over time, those concepts evolved into increasingly sophisticated systems capable of functioning inside human cells.
“Senti was founded to apply those advances to diseases where conventional therapeutic approaches have struggled, particularly cancers lacking clean, tumor-specific targets,” Dr. Lu says.
He adds that traditional therapies often face fundamental challenges—killing cancer cells without causing significant collateral damage to healthy tissue. While targeted therapies, antibody-drug conjugates, and T-cell engagers have transformed cancer treatment in many settings, many tumors still lack highly specific antigens that safely distinguish cancer cells from normal tissue.
“We believe there is a fundamentally different way to approach this problem,” Dr. Lu says. “You need a therapy that can simultaneously recognize and kill cancer cells while protecting healthy cells.”
At the center of Senti’s platform is a technology known as Logic Gates, which introduces both activating and inhibitory receptors into engineered immune cells. The activating receptor binds cancer-associated targets and triggers killing, while the inhibitory receptor suppresses activity against healthy tissues, creating what Dr. Lu describes as an “accelerator-and-brake system” that is designed to make Senti’s therapies more efficacious while maintaining high safety.
The company’s gene circuits have demonstrated functionality across both natural killer (NK) cells and T cells, allowing Senti to select the most appropriate ex vivo cell type or in vivo therapy for a given indication.
“As a company, we don’t think of ourselves as purely an NK-cell or T-cell company,” Dr. Lu says. “We think of ourselves as a Logic Gate company that solves the fundamental problem in oncology of how to kill cancer cells while sparing healthy tissues.”
Senti’s lead clinical candidate, SENTI-202, is an allogeneic, off-the-shelf CAR-NK cell therapy being developed for relapsed/refractory acute myeloid leukemia (R/R AML), a disease with poor prognosis and limited treatment options. AML remains an area of significant unmet medical need, particularly in relapsed or refractory patients where median survival is approximately five months and currently available therapies continue to generate relatively modest response rates.
Dr. Lu emphasizes that one of the longstanding challenges in AML has been the lack of clean therapeutic targets. Many antigens found on AML cells are also present on healthy bone marrow stem cells, creating a narrow therapeutic window and increasing the risk of severe bone marrow suppression.
SENTI-202 was specifically engineered to address this problem. The therapy incorporates an activating CAR receptor targeting CD33 and/or FLT3, two antigens commonly expressed on AML blasts and leukemic stem cells. At the same time, the therapy includes an inhibitory CAR designed to recognize healthy hematopoietic stem cells and suppress activity against them. An additional IL-15 armoring element is intended to enhance NK-cell activity and persistence.
Dr. Lu says that the goal is to selectively eliminate AML blasts and leukemic stem cells while preserving healthy bone marrow—a distinction that could potentially improve both efficacy and tolerability.
“In SENTI-202, we have achieved selective killing of cancer cells while protecting healthy cells at the same time, resulting in enhanced patient outcomes,” he says. “That’s the core of the Logic Gate approach.”
At the 2025 American Society of Hematology meeting, Senti presented updated Phase 1 data from an ongoing multinational, multicenter study evaluating SENTI-202 in R/R AML patients across sites in the U.S. and Australia.
The trial demonstrated a 50% overall response rate and a 42% complete remission/complete remission with partial hematologic recovery rate at the recommended Phase 2 dose, along with an estimated median duration of composite complete remission of 7.6 months.
Most notably, Dr. Lu highlights that all complete responses were measurable residual disease (MRD) negative. “In hematologic cancers, MRD negativity is extremely important because it indicates that highly sensitive methods cannot detect remaining cancer cells. We believe those deeper responses can ultimately translate into better long-term outcomes for patients.”
The company also reported a favorable safety profile, with minimal cytokine release and no neurotoxicity, adverse events that have historically complicated the use of many cell therapies. According to Senti, most treatment-related adverse events were manageable and largely limited to low-grade infusion-related reactions.
Dr. Lu points out that the safety profile may also support outpatient administration, which could become an important differentiator commercially and operationally if confirmed in later-stage studies.
Unlike autologous CAR-T therapies, which require individualized manufacturing from a patient’s own cells, SENTI-202 is manufactured as an allogeneic off-the-shelf product using healthy donor-derived NK cells. The approach is intended to simplify manufacturing, broaden patient access, and reduce treatment delays.
“We can pre-manufacture the product, cryopreserve it, and have it ready for immediate use,” Dr. Lu notes. “For AML patients, where survival timelines can be very short, reducing manufacturing time is critically important.”
He adds that the use of NK cells also addresses some of the manufacturing challenges historically associated with autologous T-cell therapies in AML patients, many of whom have already undergone multiple rounds of prior treatment and may have compromised immune systems.
Senti believes the off-the-shelf approach could eventually support broader adoption outside major academic medical centers, potentially expanding access into community oncology settings and infusion centers.
The company plans to initiate a pivotal trial for SENTI-202 in 2026 and is also exploring expansion opportunities in newly diagnosed AML, pediatric AML, and myelodysplastic syndromes. The program has already received both Regenerative Medicine Advanced Therapy designation and Orphan Drug designation from the FDA.
According to Dr. Lu, physician interest in the program has been strong, with additional clinical sites expressing interest in participating in future studies.
“We believe the combination of efficacy, safety, and outpatient potential positions SENTI-202 very favorably within the AML landscape,” he says.
While AML is currently the company’s primary focus, Dr. Lu says Senti sees broader opportunities for its gene circuit platform in both hematologic malignancies and solid tumors, particularly cancers where traditional biologic approaches have struggled because of insufficient tumor specificity.
“We are looking for cancers where clean antigen targets do not exist and where our logic-gated approach can create meaningful therapeutic differentiation,” he says.
Beyond oncology, the company is also exploring applications of its platform across additional cell and gene therapy modalities, including in vivo CAR therapies and gene therapies.
Dr. Lu explains that the broader platform includes several categories of programmable technologies designed to improve precision, safety, and controllability. These include Logic Gates, Multi-Arming technologies that allow engineered cells to deliver additional payloads such as cytokines, Regulator Dial technologies capable of switching therapies on or off using approved oral drugs, and Smart Sensors designed to activate therapies only within specific tissues or tumor environments.
Together, these technologies are intended to create increasingly programmable medicines capable of making more sophisticated biological decisions inside the body.
“We think of the cell as a mini-computer,” Dr. Lu says. “Our goal is to program next-generation medicines that can better distinguish between healthy and diseased tissue and ultimately improve outcomes for patients.”
With clinical validation now emerging for its logic-gated platform, Senti is focused on advancing SENTI-202 toward pivotal development while continuing to expand the broader potential of programmable cell and gene therapies across multiple disease areas.
“We believe this is just the beginning,” Dr. Lu contends. “Now that we have demonstrated clinical proof of concept, the opportunity is to continue expanding the platform into additional cancers and future generations of programmable medicines.”
• • • •
To connect with Senti Biosciences or any other companies featured on BioTuesdays, send us an email at editor@biotuesdays.com.
